## **AMENDMENTS TO THE CLAIMS**

Claims 1-14. (cancelled)

Claim 15. (new) A compound of the formula (I):

$$A \downarrow U \qquad \qquad \downarrow Q \qquad \qquad \downarrow$$


Docket No.: 65174(52171)

wherein

A is a heteroalkyl-, heterocycloalkyl-, heteroalkyl-cycloalkyl-, heteroaryl- or heteroarylalkyl group,

U is hydrogen, a heteroalkyl-, heterocycloalkyl-, heteroalkylcycloalkyl-, heteroaryl- or heteroaryl-alkyl group,

G-E is selected from the following groups,



or is part of an optionally substituted phenyl ring,

V-W is a group of the formula CH-CH or C=C (cis or trans),

R<sup>1</sup> is a C<sub>1</sub>-C<sub>4</sub> alkyl- or a C<sub>3</sub>-C<sub>4</sub>-cycloalkyl group,

X is oxygen or a group of the formula NR<sup>2</sup>, wherein R<sup>2</sup> is hydrogen, a alkyl-, alkenyl-, alkynyl-, hetero-alkyl-, aryl-, heteroaryl-, cycloalkyl-, alkylcyclo-alkyl-, heteroalkyl-, aralkyl- or a heteroaralkyl group,

Docket No.: 65174(52171)

Y is oxygen or a group of the formula NR<sup>10</sup>, wherein R<sup>10</sup> is hydrogen, oxygen, a OH, NH<sub>2</sub>, alkyl- or a heteroalkyl group (as for example a alkyloxy-, alkyl-amino-or dialkylamino group).

R<sup>3</sup> and R<sup>4</sup> are independently of each other hydrogen, a C<sub>1</sub>-C<sub>4</sub> alkyl group or together are part of a cycloalkyl group with 3 or 4 ring atoms,

R<sup>9</sup> is hydrogen, a alkyl-, alkenyl-, alkynyl-, heteroalkyl-, aryl-, heteroaryl-, cycloalkyl-, alkyl-cycloalkyl-, heteroalkylcycloalkyl-, heterocyclo-alkyl-, aralkyl- or a heteroaralkyl group,

or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof.

Claim 16. (New) A compound of claim 15 wherein A is a group of the formula -C(CH<sub>3</sub>)=CHR<sup>5</sup> or -CH=CHR<sup>5</sup>, wherein R<sup>5</sup> is a heteroaryl- or a heteroarylalkyl group.

Claim 17. (New) A compound of claim 15 wherein A is a group of the formula (II) or (III):

$$R^6 \longrightarrow N$$
(III)
 $R^6 \longrightarrow N$ 
(IIII)

wherein

Q a sulphur, oxygen or a group of the formula  $NR^7$  wherein  $R^7$  is hydrogen, a  $C_1$ - $C_4$  alkyl group or a  $C_1$ - $C_4$ -heteroalkyl group, z is nitrogen or a CH group and  $R^6$  is a group of the formula  $OR^8$  or  $NHR^8$ , a alkyl-, alkenyl, alkinyl- or a heteroalkyl group, wherein  $R^8$  is hydrogen, a  $C_1$ - $C_4$ -alkyl group or a  $C_1$ - $C_4$ -heteroalkyl group.

Claim 18. (New) A compound of claim 17 wherein z is a CH-group.

Application No. National Phase of PCT/EP2004/010820 Amendment dated March 23, 2006 First Preliminary Amendment Page 4

Claim 19. (New) A compound of claim 17 wherein Q is sulphur or oxygen.

Claim 20. (New) A compound of claim 17 wherein R<sup>6</sup> is a group of the formula CH<sub>3</sub>, CH<sub>2</sub>OH or CH<sub>2</sub>NH<sub>2</sub>.

Docket No.: 65174(52171)

Claim 21. (New) A compound of claim 15 wherein X is oxygen.

Claim 22. (New) A compound of claim 15 wherein R<sup>1</sup> is a methyl group.

Claim 23. (New) A compound of claim 15 wherein  $\mathbb{R}^3$  and  $\mathbb{R}^4$  are methyl groups.

Claim 24. (New) A compound of claim 15 wherein U is hydrogen.

Claim 25. (New) A compound of claim 15 wherein R<sup>9</sup> is hydrogen.

Claim 26. (New) A compound of claim 15 wherein Y is oxygen or a group of the formula NH, NOH or NO.

Claim 27. (New) A pharmaceutical composition comprising a compound of claim 15.

Claim 28. (New) The pharmaceutical composition of claim 27 further comprising one or more carriers and/or adjuvants.

Claim 29. (New) A method for treating a patient suffering from or susceptible to cancer comprising administering to the patient an effective amount of claim 15.

Claim 30. (New) The method of claim 29 wherein the patient is suffering from cancer.

Application No. National Phase of PCT/EP2004/010820 Amendment dated March 23, 2006 First Preliminary Amendment Page 5

Claim 31. (New) The method of claim 29 wherein the patient has been identified as suffering from cancer and selected for treatment for cancer and the compound is administered to identified and selected patient.

Docket No.: 65174(52171)